PharmaCare Alliance

GenericsBiosimilarsPharmaceutical Manufacturing

20 provisions tracked

12 positive

3 negative

1 conflict

PositiveSec. CMS-2026-0089 · CMS Medicare Drug Price Negotiation

Medicare Part D Negotiation Methodology Update

Lower brand-name drug prices accelerate biosimilar adoption timelines. PharmaCare members positioned to capture market share post-negotiation.

ACTION: Brief PharmaCare members on market opportunity analysis. Prepare biosimilar readiness timeline for top 5 negotiated drugs.

$4.8B estimated savings over 10 years

PositiveSec. CMS-2026-0142 · CMS Medicare Part B Payment Reform

Medicare Part B Drug Payment Rate Adjustment

Biosimilar infusion products become more cost-competitive under ASP+3%. Hospitals incentivized to switch to lower-cost biosimilar alternatives.

ACTION: Develop hospital switching toolkit for top biosimilar infusion products. Brief member companies on market acceleration opportunity.

$2.1B estimated savings over 5 years

PositiveSec. HR-4521 · Legislative — Biosimilar Competition

Biosimilar Competition Act

Core legislative priority for PharmaCare. 180-day interchangeable exclusivity rewards first-movers. 8 PharmaCare members have biosimilars in FDA pipeline that benefit directly.

ACTION: Coordinate with Grassley and Klobuchar offices on Senate companion bill. Prepare floor vote whip strategy.

$1.2B CBO-scored savings over 10 years

PositiveSec. S-2847 · Legislative — Drug Pricing

Prescription Drug Affordability Act

Generic and biosimilar manufacturers largely exempt from price increase penalties. Creates competitive advantage vs. brand-name manufacturers.

ACTION: Support legislation while advocating for generic supply chain investment provisions. Brief Grassley staff on generic market sustainability.

$6.3B CBO-scored savings over 10 years

PositiveSec. CMS-2026-0178 · CMS IRA Drug Negotiation

IRA Drug Negotiation List Expansion (Round 3)

Negotiated drug prices create larger price gap favoring biosimilar alternatives. PharmaCare members with biosimilars for listed drugs see accelerated market opportunity.

ACTION: Develop market capture strategy for biosimilars of Round 3 listed drugs. Brief member companies on pricing advantage timelines.